These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1265 related articles for article (PubMed ID: 21605038)

  • 1. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
    Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
    Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.
    Moore KBE; Hung TJ; Fortin JS
    Drug Discov Today; 2023 Mar; 28(3):103487. PubMed ID: 36634842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Neurotoxic Role of Extracellular Tau Protein.
    Sebastián-Serrano Á; de Diego-García L; Díaz-Hernández M
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.
    Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Sarmiento J; Troncoso J; Jackson GR; Kayed R
    FASEB J; 2012 May; 26(5):1946-59. PubMed ID: 22253473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granular tau oligomers as intermediates of tau filaments.
    Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
    Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau as a therapeutic target for Alzheimer's disease.
    Boutajangout A; Sigurdsson EM; Krishnamurthy PK
    Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azure C Targets and Modulates Toxic Tau Oligomers.
    Lo Cascio F; Kayed R
    ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of NFT: Biochemical Approach.
    Hasegawa M
    Adv Exp Med Biol; 2019; 1184():23-34. PubMed ID: 32096025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
    Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
    ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
    Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
    Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
    Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
    J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.